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BACKGROUND
Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and 
hyperinflammation, including elevated interleukin-6 levels. The use of tocilizu-
mab, a monoclonal antibody against the interleukin-6 receptor, has resulted in 
better outcomes in patients with severe Covid-19 pneumonia in case reports and 
retrospective observational cohort studies. Data are needed from randomized, 
placebo-controlled trials.
METHODS
In this phase 3 trial, we randomly assigned patients who were hospitalized with 
severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of 
tocilizumab (at a dose of 8 mg per kilogram of body weight) or placebo. Approxi-
mately one quarter of the participants received a second dose of tocilizumab or 
placebo 8 to 24 hours after the first dose. The primary outcome was clinical status 
at day 28 on an ordinal scale ranging from 1 (discharged or ready for discharge) 
to 7 (death) in the modified intention-to-treat population, which included all the 
patients who had received at least one dose of tocilizumab or placebo.
RESULTS
Of the 452 patients who underwent randomization, 438 (294 in the tocilizumab 
group and 144 in the placebo group) were included in the primary and secondary 
analyses. The median value for clinical status on the ordinal scale at day 28 was 
1.0 (95% confidence interval [CI], 1.0 to 1.0) in the tocilizumab group and 2.0 
(non-ICU hospitalization without supplemental oxygen) (95% CI, 1.0 to 4.0) in the 
placebo group (between-group difference, −1.0; 95% CI, −2.5 to 0; P = 0.31 by the 
van Elteren test). In the safety population, serious adverse events occurred in 103 
of 295 patients (34.9%) in the tocilizumab group and in 55 of 143 patients (38.5%) 
in the placebo group. Mortality at day 28 was 19.7% in the tocilizumab group and 
19.4% in the placebo group (weighted difference, 0.3 percentage points (95% CI, 
–7.6 to 8.2; nominal P = 0.94).
CONCLUSIONS
In this randomized trial involving hospitalized patients with severe Covid-19 pneu-
monia, the use of tocilizumab did not result in significantly better clinical status 
or lower mortality than placebo at 28 days. (Funded by F. Hoffmann–La Roche and 
the Department of Health and Human Services; COVACTA ClinicalTrials.gov num-
ber, NCT04320615.)
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C
oronavirus disease 2019 (COVID-19) 
has rapidly developed into a global health 
threat since emerging in China in late 
2019.1 Severe Covid-19 pneumonia, which occurs 
in approximately 15% of patients infected with 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), is associated with high mortality 
and places extensive burden on intensive care 
units (ICUs) to provide mechanical ventilation 
and other advanced forms of life support.2,3 As 
was observed in patients with Middle East re-
spiratory syndrome and SARS-CoV-1,4 Covid-19 
can begin with an initial phase of high viral 
replication that is followed by a second phase 
that may be driven by the host immune re-
sponse.5 This progression can lead to a rapid 
increase in proinflammatory cytokines, an un-
controlled inflammatory response, acute respi-
ratory distress syndrome (ARDS), and multiple 
organ failure.4,6
Levels of interleukin-6 correlate with Covid-19 
severity,7,8 which suggests that immune dysregu-
lation and ARDS may be influenced by interleu-
kin-6.6,9 The accumulation of lymphocytes and 
inflammatory monocytes, endotheliitis, apopto-
sis, thrombosis, and angiogenesis in the pulmo-
nary vasculature in patients with Covid-19 sug-
gests that vascular inflammation and dysfunction 
contribute to the pathophysiological features of 
severe Covid-19 pneumonia.10,11 Since interleukin-6 
promotes endothelial dysfunction and the devel-
opment of vascular permeability, this cytokine 
may play a role in the vascular dysfunction as-
sociated with this disease.12
The potential role of interleukin-6 in Covid-19 
pneumonia6,9 provides a rationale for the investi-
gation of interleukin-6 signaling inhibitors. Toci-
lizumab is a monoclonal antibody against inter-
leukin-6 receptor-alpha that is used to treat 
certain inflammatory diseases.13 Better outcomes 
in patients with severe Covid-19 pneumonia who 
received tocilizumab have been observed in case 
reports14-16 and supported by retrospective obser-
vational cohort studies that showed a rapid re-
duction in fever, a reduced use of oxygen support 
and mechanical ventilation, and a reduction in 
lung manifestations.17-23 We conducted COVACTA, 
a phase 3, international, randomized, double-
blind, placebo-controlled trial, to assess the ef-
ficacy and safety of tocilizumab in hospitalized 
patients with severe Covid-19 pneumonia.
Me thods
Trial Design and Randomization
In this trial, which was conducted at 62 hospi-
tals in nine countries in Europe and North 
America (Canada, Denmark, France, Germany, 
Italy, the Netherlands, Spain, the United King-
dom, and the United States), we enrolled adults 
(≥18 years of age) with severe Covid-19 pneumo-
nia, as confirmed by positive polymerase-chain-
reaction (PCR) assay of any body fluid and evi-
denced by bilateral chest infiltrates on chest 
radiography or computed tomography. Eligible 
patients had a blood oxygen saturation of 93% 
or less or a ratio of the partial pressure of oxy-
gen to the fraction of inspired oxygen of less 
than 300 mm Hg. Patients were excluded if the 
treating physician determined that death was 
imminent and inevitable within 24 hours or if 
they had active tuberculosis or a bacterial, fun-
gal, or viral infection other than SARS-CoV-2. 
Standard care according to local practice (anti-
viral treatment, low-dose glucocorticoids, conva-
lescent plasma, and supportive care) was pro-
vided. However, concomitant treatment with 
another investigational agent (except antiviral 
drugs) or any immunomodulatory agent was 
prohibited. Written informed consent was ob-
tained from all the patients or, if written consent 
could not be provided, the patient’s legally au-
thorized representative could provide oral con-
sent with appropriate documentation by the in-
vestigator.
Eligible patients were randomly assigned in a 
2:1 ratio to receive a single intravenous infusion 
of tocilizumab (at a dose of 8 mg per kilogram of 
body weight, with a maximum dose of 800 mg) 
or placebo plus standard care by means of an 
interactive voice or Web-based response system 
and permuted-block randomization. Randomiza-
tion was stratified according to geographic re-
gion (North America or Europe) and the use of 
mechanical ventilation (yes or no). If clinical 
signs or symptoms did not improve or worsened 
(defined as sustained fever or worsened clinical 
status on an ordinal scale), a second infusion of 
tocilizumab or placebo could be administered 
8 to 24 hours after the first dose. The primary 
analysis was performed at day 28, and the final 
trial visit occurred at day 60. Additional details 
regarding the trial design are provided in the 
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protocol document (which includes the statisti-
cal analysis plan), available with the full text of 
this article at NEJM.org.
Evaluations
For the evaluation of patients in this trial, base-
line was defined as the last observation before 
the administration of tocilizumab or placebo on 
day 1. The patients’ clinical status was assessed 
on an ordinal scale according to the following 
categories: 1, discharged or ready for discharge; 
2, hospitalization in a non–intensive care unit 
(ICU) without supplemental oxygen; 3, non–ICU 
hospitalization with supplemental oxygen; 4, ICU 
or non–ICU hospitalization with noninvasive ven-
tilation or high-flow oxygen; 5, ICU hospitaliza-
tion with intubation and mechanical ventilation; 
6, ICU hospitalization with extracorporeal mem-
brane oxygenation or mechanical ventilation and 
additional organ support; and 7, death. Clinical 
status was recorded at baseline and every day 
during hospitalization.
Patients were also evaluated according to the 
level of clinical severity on the National Early 
Warning Score 2, which is a standardized as-
sessment for identifying acutely ill patients on 
the basis of respiration rate, oxygen saturation, 
systolic blood pressure, pulse rate, level of con-
sciousness, and temperature; values on this in-
strument range from 0 to 20, with higher scores 
indicating greater clinical risk.
Outcome Measures
The primary efficacy outcome was clinical status 
at day 28, as assessed on the seven-category or-
dinal scale. Key secondary efficacy outcomes 
were clinical status at day 14 on the ordinal 
scale, mortality at day 28, number of ventilator-
free days by day 28, the time to improvement 
from baseline by at least two categories on the 
ordinal scale, and the time to hospital discharge 
or readiness for discharge; the latter was de-
fined as a normal body temperature and respira-
tory rate and stable oxygen saturation while 
breathing ambient air or 2 liters or less of sup-
plemental oxygen. Other secondary outcomes 
were the time until clinical failure, which was 
defined as death, discontinuation from trial 
participation during hospitalization, initiation of 
mechanical ventilation, or ICU transfer or a 1-cat-
egory worsening of clinical status in patients who 
were receiving mechanical ventilation or who were 
in the ICU at baseline; the initiation of mechan-
ical ventilation among patients who were not 
receiving mechanical ventilation at randomiza-
tion; the incidence of ICU transfer among pa-
tients who were not in an ICU at baseline; and 
the duration of ICU stay. Adverse events were 
recorded according to the system organ class 
and preferred terms in the Medical Dictionary for 
Regulatory Activities, version 23.0.
Trial Oversight
The trial was conducted in accordance with the 
Good Clinical Practice guidelines of the Interna-
tional Council for Harmonisation E6 and the 
principles of the Declaration of Helsinki or local 
regulations, whichever afforded greater patient 
protection. The protocol was reviewed by the 
institutional review board or ethics committee at 
each site.
The first draft of the manuscript was written 
by the penultimate author, with writing support 
provided by ApotheCom and funded by the 
sponsor, F. Hoffmann–La Roche. The data were 
analyzed by the sponsor. The authors had access 
to all the data for the patients who were enrolled 
at their trial site. All the authors made the deci-
sion to submit the manuscript for publication 
and vouch for the completeness and accuracy of 
the data and for the adherence of the trial to the 
protocol.
Statistical Analysis
We performed efficacy assessments of the pri-
mary and secondary outcomes in the modified 
intention-to-treat population, which included all 
the patients who had undergone randomization 
and received a dose of tocilizumab or placebo. 
We calculated that a sample size of 450 patients 
would provide a power of 90% to determine a 
between-group difference in the primary outcome 
(clinical status at day 28), assuming a distribu-
tion on the ordinal scale that corresponded to an 
odds ratio of 2.0. If significance was met, we 
tested mortality at day 28 at the 5% level using 
a hierarchical approach, but no other adjustment 
for multiple comparisons was planned. In the sta-
tistical analysis plan, up to three interim efficacy 
analyses were specified but were not performed 
because of rapid enrollment.
The analyses were stratified according to re-
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gion and mechanical-ventilation status at ran-
domization, except for some subgroup analyses, 
as prespecified. For the primary outcome of 
clinical status at day 28, we compared the distri-
bution on the ordinal scale using a nonparamet-
ric van Elteren test. We used a proportional-odds 
model to calculate odds ratios and 95% confi-
dence intervals to determine the odds of being 
in a better clinical-status category in the tocilizu-
mab group than in the placebo group. A multi-
ple-imputation approach was used to handle 
missing data and was implemented by means of 
bootstrapping. This approach assumed that data 
were missing at random within strata and trial 
group. (Details regarding these methods are 
provided in the Methods section in the Supple-
mentary Appendix, available at NEJM.org.)
We used the Cochran–Mantel–Haenszel test 
to analyze differences in mortality and incidence 
of mechanical ventilation and ICU transfer, the 
van Elteren test to assess differences in the num-
ber of ventilator-free days, and a log-rank test 
and Kaplan–Meier plots to assess secondary 
outcomes in time-to-event analyses. Data regard-
ing deaths were censored at day 28 for all time-
to-event analyses involving clinical improve-
ment. Patients who had died by day 28 were 
considered to have had no ventilator-free days.24 
Patients who had died or discontinued participa-
tion in the trial before discharge by day 28 were 
assumed to have required mechanical ventilation 
or ICU transfer for the respective incidence analy-
ses. Cumulative incidence plots were generated 
with the use of the nonparametric Aalen–Johansen 
estimator, in which death is a competing risk, 
and additional cause-specific Cox regression 
was performed.
Safety was assessed in the population that 
included all the patients who had received a dose 
of tocilizumab or placebo, according to the trial 
agent that was first received. Patients who re-
ceived either tocilizumab or placebo in error 
were included in the safety analysis.
R esult s
Patients
From April 3, 2020, through May 28, 2020, a 
total of 479 patients underwent screening. Of 
these patients, 452 patients underwent random-
ization, and 438 were included in the modified 
intention-to-treat population (294 in the tocilizu-
mab group and 144 in the placebo group) (Fig. 1). 
The number of patients who underwent random-
ization at each of the 62 trial sites ranged from 
1 to 25. The safety population included 295 and 
143 patients, respectively, because 1patient who 
was assigned to receive placebo received tocilizu-
mab. The 28-day follow-up evaluation was com-
pleted in 224 of 294 patients (76.2%) in the toci-
lizumab group and in 108 of 144 patients 
(75.0%) in the placebo group. In addition to the 
patients who died, trial discontinuation before 
day 28 occurred in 13 patients (4.4%) in the 
tocilizumab group and in 9 (6.3%) in the placebo 
group. None of the patients discontinued par-
ticipation because of safety reasons.
Baseline demographic and disease character-
istics were generally well balanced in the two 
trial groups. Approximately 70% of the patients 
in each group were men; in the tocilizumab 
group, 176 patients (59.9%) were White and 40 
(13.6%) were Black, as compared with 76 (52.8%) 
and 26 (18.1%), respectively, in the placebo group. 
The mean (±SD) age was 60.9±14.6 years in the 
tocilizumab group and 60.6±13.7 years in the 
placebo group.
A lower percentage of patients received gluco-
corticoids in the tocilizumab group than in the 
placebo group both at baseline (57 [19.4%] vs. 41 
[28.5%]) (Table 1) and during the trial (99 
[33.7%] vs. 75 [52.1%]). The percentages of pa-
tients who received antiviral treatment were 
similar in the tocilizumab group and the placebo 
group, both at baseline (71 [24.1%] vs. 42 [29.2%]) 
and during the trial (68 [23.1%] vs. 35 [24.3%]). 
Convalescent plasma was administered during 
the trial to 10 patients (3.4%) in the tocilizumab 
group, including 5 (1.7%) at baseline, and in 
6 patients (4.2%) in the placebo group, including 
1 (0.7%) at baseline. A second dose of tocilizu-
mab or placebo was administered to 65 patients 
(22.1%) in the tocilizumab group and 43 pa-
tients (29.9%) in the placebo group.
Primary Outcome
The median value for clinical status on the ordi-
nal scale at day 28 was 1.0 (95% confidence in-
terval [CI], 1.0 to 1.0) in the tocilizumab group 
and 2.0 (non-ICU hospitalization without supple-
mental oxygen) (95% CI, 1.0 to 4.0) in the pla-
cebo group (between-group difference, −1.0; 
95% CI, −2.5 to 0; P = 0.31 by the van Elteren 
test) (Table 2, and Fig. S1 in the Supplementary 
The New England Journal of Medicine 
Downloaded from nejm.org on March 3, 2021. For personal use only. No other uses without permission. 
 Copyright © 2021 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 5
Tocilizumab in Patients with Covid-19 Pneumonia
Appendix). The percentage of patients who had 
missing data for the primary outcome was 3.7% 
in the tocilizumab group and 2.1% in the placebo 
group. In a prespecified analysis of the primary 
data (last postbaseline observation carried for-
ward for missing data), the results were similar 
to those with the multiple-imputation approach 
(P = 0.36 by the van Elteren test) (Table S1).
Figure 1. Enrollment and Outcomes.
One patient who was assigned to the placebo group received tocilizumab; this patient was included in the placebo group for analyses 
performed in the modified intention-to-treat population (mITT) and in the tocilizumab group for analyses performed in the safety popu-
lation. One patient in each trial group died after they had withdrawn from the trial; therefore, for these patients, death is not listed as 
the reason for discontinuation. PaO2:FIO2 denotes the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen, 
SpO2 oxygen saturation, ULN upper limit of the normal range, and WHO World Health Organization.
452 Underwent randomization
479 Patients were assessed for eligibility
27 Were excluded
2 Were unable to comply with protocol criteria
1 Had liver aminotransferase level >10×ULN
1 Had serious medical condition
1 Received oral antirejection or immuno-
modulatory therapy within 6 mo
3 Did not meet WHO Covid-19 pneumonia
criteria
1 Did not have SpO2 ≤93% or PaO2:FiO2
<300 mm Hg
10 Had suspected active bacterial, fungal,
viral, or other infection
8 Had other reason (withdrawal of consent,
positive viral swab >7 days, laboratory values
entered in error, death before screening) 
301 Were assigned to receive tocilizumab 151 Were assigned to receive placebo





2 Had other reason






1 Had other reason
70 (24%) Discontinued trial
on or before day 28
57 (19%) Died





295 Were included in
the safety population




36 (25%) Discontinued trial
on or before day 28
27 (19%) Died
5 (3%) Were lost to
follow-up 
2 (1%) Withdrew
2 (1%) Were withdrawn
by physician
108 (75%) Completed the trial to day 28224 (76%) Completed the trial to day 28
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Male sex — no. (%) 205 (69.7) 101 (70.1)
Age
Mean — yr 60.9±14.6 60.6±13.7
Distribution — no. (%)
18–64 yr 163 (55.4) 81 (56.2)
65–84 yr 117 (39.8) 60 (41.7)
≥85 yr 14 (4.8) 3 (2.1)
Weight — kg 88.9±23.6 88.1±24.3
Race or ethnic group — no. (%)†
American Indian or Alaska Native 8 (2.7) 5 (3.5)
Asian 28 (9.5) 10 (6.9)
Black 40 (13.6) 26 (18.1)
Native Hawaiian or other Pacific Islander 3 (1.0) 5 (3.5)
White 176 (59.9) 76 (52.8)
Multiple 0 1 (0.7)
Unknown 39 (13.3) 21 (14.6)
Region — no. (%)
Europe 120 (40.8) 59 (41.0)
North America 174 (59.2) 85 (59.0)
Illness severity on National Early Warning Score 2‡ 7.1±3.0 7.0±3.0
Ordinal scale for clinical status — no. (%)§
2 9 (3.1) 6 (4.2)
3 78 (26.5) 44 (30.6)
4 94 (32.0) 39 (27.1)
5 45 (15.3) 15 (10.4)
6 68 (23.1) 40 (27.8)¶
Interleukin-6 — ng/liter‖
No. of patients with data 233 100
Mean value 201.9±418.4 195.4±368.2
Median (range) 88.1 (3.1–4020) 71.2 (3.1–2810)
C-reactive protein — mg/liter
No. of patients with data 237 125
Mean value 168.4±101.4 172.6±114.0
Median (range) 157.2 (1.1–446.6) 150.3 (1.6–499.6)
Ferritin — pmol/ml
No. of patients with data 241 128
Mean value 6891±106,736 4027±45,431
Median (range) 2.3 (0.0–1,657,000) 2.2 (0.1–514,000)
Mechanical ventilation
Patients — no. (%) 111 (37.8) 54 (37.5)
No. of days between initiation and randomization**
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No. of patients with data 107 51
Mean no. 5.1±5.5 4.3±4.5
Median (range) 3.0 (0.0–28.0) 3.0 (0.0–20.0)
Symptoms at diagnosis — no. (%)
Fever 193 (65.6) 98 (68.1)
Cough 216 (73.5) 102 (70.8)
Shortness of breath 213 (72.4) 93 (64.6)
Gastrointestinal 96 (32.7) 41 (28.5)
Headache 37 (12.6) 21 (14.6)
Fatigue 91 (31.0) 44 (30.6)
Coexisting illness — no. (%)††
≥1 Diagnosis 231 (78.6) 124 (86.1)
Obesity 63 (21.4) 27 (18.8)
Diabetes 105 (35.7) 62 (43.1)
Cardiovascular impairment 88 (29.9) 35 (24.3)
Hypertension 178 (60.5) 94 (65.3)
Hepatic impairment 6 (2.0) 2 (1.4)
Chronic lung disease 49 (16.7) 22 (15.3)
No. of days from onset of Covid-19 symptoms
No. of patients with data 291 143
Mean no. 12.1±6.6 11.4±6.9
Median (range) 11.0 (1.0–49.0) 10.0 (2.0–50.0)
Other treatments — no. (%)‡‡
Glucocorticoids 57 (19.4) 41 (28.5)
Antiviral drugs 71 (24.1) 42 (29.2)
Convalescent plasma 5 (1.7) 1 (0.7)
*  Plus–minus values are means ±SD. For the evaluation of patients, baseline was defined as the last observation before 
the administration of tocilizumab or placebo on day 1.
†  Race or ethnic group was reported by the patients.
‡  Scores for illness severity on the National Early Warning Score 2 evaluation range from 0 to 20, with higher scores 
indicating greater clinical risk.
§  The patients’ clinical status was assessed on an ordinal scale as follows: 1, discharged or ready for discharge; 2, hos-
pitalization in a non–intensive care unit (ICU) without supplemental oxygen; 3, non–ICU hospitalization with supple-
mental oxygen; 4, ICU or non–ICU hospitalization with noninvasive ventilation or high-flow oxygen; 5, ICU hospital-
ization with mechanical ventilation; 6, ICU hospitalization with extracorporeal membrane oxygenation or mechanical 
ventilation and additional organ support; and 7, death. No patients were in categories 1 or 7 at baseline.
¶  Included in this category is a patient who died on trial day 1 (ordinal category 7) but was listed in category 6 on day 1 
before death.
‖  Values below the lower limit of quantitation of 3.12 ng per liter were set at this value.
**  The number of days that patients were receiving mechanical ventilation before baseline were counted from the re-
corded initiation of intubation to the day before trial day 1. The earliest start date was used if multiple procedures 
were recorded. Patients who were first intubated on trial day 1 were categorized as having received mechanical ven-
tilation for 0 days before baseline.
††  Coexisting conditions were coded according to the terms used in the Medical Dictionary for Regulatory Activities, ver-
sion 23.0.
‡‡  Listed here are any treatments that were administered during the period from trial day −7 until the initiation of tocilizu-
mab or placebo on day 1. The use of glucocorticoids includes only systemic use. Antiviral drugs included lopinavir–
ritonavir, remdesivir, lopinavir, ritonavir, chloroquine, hydroxychloroquine, and hydroxychloroquine sulfate.
Table 1. (Continued.)
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The prespecified point estimate of the treat-
ment effect for the primary outcome was an 
odds ratio; the assumption of proportional odds 
was not met for this analysis (P = 0.0005 for trial 
group). Therefore, odds ratios should not be 
used for statistical comparisons. The odds ratios 
are provided in Table S2 for a complete represen-
tation of the planned analyses. Observed propor-
tions and fitted data from the model are pro-
vided in Figure S2 and Table S3.
Secondary Outcomes
At day 14, the median value for clinical status on 
the seven-category ordinal scale was 3.0 (95% 
CI, 2.0 to 4.0) in the tocilizumab group and 4.0 
(95% CI, 3.0 to 5.0) in the placebo group, for a 
between-group difference of −1.0 (95% CI, −2.0 
to 0.5) (Table 2 and Fig. S3A). Death was re-
ported by day 28 in 58 patients (19.7%) in the 
tocilizumab group and in 28 (19.4%) in the pla-
cebo group, for a weighted difference of 0.3 








(95% CI) P Value
Primary outcome
Median value for clinical status on 7-category 
ordinal scale at day 28 (95% CI)
1.0 (1.0 to 1.0) 2.0 (1.0 to 4.0) –1.0 (–2.5 to 0.0) 0.31†
Secondary outcomes
Median value for clinical status at day 14 on 
7-category ordinal scale (95% CI)‡
3.0 (2.0 to 4.0) 4.0 (3.0 to 5.0) –1.0 (–2.0 to 0.5)
Death at day 28 — no. (%) 58 (19.7) 28 (19.4) 0.3 (–7.6 to 8.2)§ 0.94
Median no. of days until hospital discharge or 
readiness for discharge (95% CI)
20.0 (17.0 to 27.0) 28.0 (20.0 to NE) 1.35 (1.02 to 1.79)¶
Median no. of days until improvement by ≥2 
categories on 7-category ordinal scale in 
clinical status (95% CI)
14.0 (12.0 to 17.0) 18.0 (15.0 to 28.0) 1.26 (0.97 to 1.64)¶
Median no. of days in ICU (95% CI) 9.8 (7.0 to 15.7) 15.5 (8.7 to 25.5) –5.8 (–15.0 to 2.9)
Incidence of ICU stay among patients not in 
ICU at baseline — no./total no. (%)
27/127 (21.3) 23/64 (35.9) –14.8 (–28.6 to –1.0)‖
Median no. of ventilator-free days at day 28 
(95% CI)
22.0 (18.0 to 28.0) 16.5 (11.0 to 26.0) 5.5 (–2.8 to 13.0)
Incidence of mechanical ventilation among pa-
tients not receiving mechanical ventilation 
at randomization — no./total no. (%)
51/183 (27.9) 33/90 (36.7) –8.9% (–20.7 to 3.0)‖
Clinical failure among patients not receiving 
mechanical ventilation at randomization — 
no./total no. (%)**
53/183 (29.0) 38/90 (42.2) 0.61 (0.40 to 0.94)††
*  Primary and secondary efficacy outcomes were analyzed in the modified intention-to-treat population. ICU denotes intensive care unit, 
and NE not evaluable.
†  This P value was calculated by means of the van Elteren test stratified according to region and the presence or absence of mechanical 
 ventilation at randomization.
‡  In this category, the last observation was carried forward for missing data.
§  This weighted difference in percentages was calculated with the use of the Cochran–Mantel–Haenszel test stratified according to region 
and the presence or absence of mechanical ventilation at randomization.
¶  This value is a hazard ratio that was calculated by means of a Cox proportional-hazards model stratified according to region and the pres-
ence or absence of mechanical ventilation at randomization.
‖  This weighted difference in percentages was calculated with the use of the Cochran–Mantel–Haenszel test stratified according to region  
at randomization.
**  Clinical failure was defined as death, withdrawal from the trial during hospitalization, transfer to the ICU, or the initiation of invasive me-
chanical ventilation by 28 days.
††  This value is a hazard ratio that was calculated by means of a Cox proportional-hazards model stratified according to region. This post hoc 
analysis was not prespecified.
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percentage points (95% CI, −7.6 to 8.2; P = 0.94). 
The median number of ventilator-free days was 
22.0 (95% CI, 18.0 to 28.0) with tocilizumab and 
16.5 (95% CI, 11.0 to 26.0) with placebo, for a 
difference of 5.5 days (95% CI, −2.8 to 13.0) (Fig. 
S4 and Table S6). The median time from base-
line until patients had an improvement by at 
least two categories on the seven-category ordi-
nal scale was 14 days (95% CI, 12 to 17) in the 
tocilizumab group and 18 days (95% CI, 15 to 
28) in the placebo group (Cox proportional-
hazards ratio, 1.26; 95% CI, 0.97 to 1.64) 
(Fig. 2A and Table S7). The median time until 
patients were discharged from the hospital or 
ready to be discharged was 20 days (95% CI, 17 
to 27) in the tocilizumab group and 28 days 
(95% CI, 20 to not evaluable) in the placebo 
group (Cox proportional-hazards ratio, 1.35; 
95% CI, 1.02 to 1.79) (Fig. 2B and Table S7). The 
median duration of ICU stay was 9.8 days in the 
tocilizumab group and 15.5 days in the placebo 
group, for a difference of 5.8 days (95% CI, –15.0 
to 2.9). Data regarding the time to improvement 
in clinical status, time to hospital discharge or 
readiness for discharge, and mortality are pro-
vided in Figure S5.
Subgroup Analyses
Among the patients who were receiving mechani-
cal ventilation at randomization, the median 
value for clinical status on the ordinal scale at 
day 28 was 5.0 (95% CI, 3.0 to 5.0) in the tocilizu-
mab group (in 111 patients) and 5.0 (95% CI, 4.0 
to 6.0) in the placebo group (in 54 patients). 
Among the patients who were not receiving me-
chanical ventilation at randomization, the me-
dian value for clinical status at day 28 was 1.0 
(95% CI, 1.0 to 1.0) in both the tocilizumab 
group (in 183 patients) and the placebo group 
(in 90 patients) (Fig. S6). Clinical status at day 
28 and day 14 according to the ordinal-scale 
category at baseline are presented in Figure 2C 
and Figure S3B, respectively.
Among the patients who were not receiving 
mechanical ventilation at randomization, the ini-
tiation of the procedure during the trial oc-
curred in 51 of 183 patients (27.9%) in the toci-
lizumab group and in 33 of 90 patients (36.7%) 
in the placebo group, for a weighted difference 
of –8.9 percentage points (95% CI, –20.7 to 3.0). 
Among the patients who were not being treated 
in the ICU at baseline, transfer to the ICU oc-
curred in 27 of 127 patients (21.3%) in the toci-
lizumab group and in 23 of 64 patients (35.9%) 
in the placebo group, for a weighted difference 
of –14.8 percentage points (95% CI, –28.6 to 
–1.0). In a post hoc analysis, among the patients 
who were not receiving mechanical ventilation at 
baseline, clinical failure (as defined in the Meth-
ods section) occurred in 53 of 183 patients 
(29.0%) in the tocilizumab group and in 38 of 
90 patients (42.2%) in the placebo group (hazard 
ratio, 0.61; 95% CI, 0.40 to 0.94).
Safety
In the safety population, adverse events were 
reported in 77.3% of 295 patients in the tocilizu-
mab group and in 81.1% of 143 patients in the 
placebo group through day 28 (Table 3); serious 
adverse events were reported in 34.9% and 
38.5%, respectively. Fatal events occurred in 58 
patients (19.7%) in the tocilizumab group and in 
28 (19.6%) in the placebo group through day 28. 
The most commonly reported cause of death 
was Covid-19 pneumonia. Adverse events of spe-
cial interest with respect to tocilizumab were 
generally well balanced between the trial groups. 
No patients who received tocilizumab had ana-
phylaxis. By day 28, 76 serious infections were 
reported in 62 patients (21.0%) in the tocilizu-
mab group and 49 serious infections in 37 pa-
tients (25.9%) in the placebo group. Similar per-
centages of patients in each trial group had 
adverse events and serious adverse events at the 
clinical cutoff date of June 24, 2020 (Tables S8 
and S9).
Discussion
In this trial involving hospitalized patients with 
severe Covid-19 pneumonia, we found no sig-
nificant difference in clinical status between the 
tocilizumab group and the placebo group at day 
28. No mortality benefit was associated with the 
use of tocilizumab, although the trial was not 
powered for this outcome. No safety concerns 
associated with tocilizumab in this population 
were observed. The data suggested a possible 
benefit for tocilizumab in the time until hospital 
discharge (or readiness for discharge) and in the 
duration of ICU stay, both of which require ad-
ditional study. Adverse events, including those of 
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special interest for tocilizumab (bleeding, hepat-
ic, and cardiac events), were generally well bal-
anced in the two trial groups, and the incidenc-
es of infections or serious infections were lower 
in the tocilizumab group.
The design and conduct of clinical trials in-
volving patients with Covid-19 present unique 
challenges and limitations. Our trial population 
was intentionally chosen to be heterogeneous 
with regard to demographic and clinical charac-
teristics, previous or concurrent treatments, and 
disease severity to allow for an assessment of 
potential benefit across a broad range of pa-
tients and to reflect real-world practice in the 
expanding pandemic. This heterogeneity is re-
f lected in the wide range of values for interleu-
kin-6, C-reactive protein (CRP), and ferritin at 
baseline (Table 1). Median values were consis-
tent with those in studies involving patients with 
severe or critical Covid-19 pneumonia.7,25,26 De-
spite this heterogeneity, the percentage of pa-
tients who were discharged or ready for dis-
charge by day 28 was higher in the tocilizumab 
group than in the placebo group across the 
baseline ordinal scale of clinical-status catego-
ries, whereas no consistent pattern was observed 
for mortality.
Clinical status on the ordinal scale was cho-
sen as the primary outcome because it integrat-
ed several outcomes that are potentially impor-
tant in the management of a pandemic illness, 
including the time until hospital discharge, esca-
lating levels of inpatient care, and death. How-
ever, this outcome has important limitations, 
including sensitivity to differences in local clini-
cal practice, lack of proportionality between 
categories, insensitivity to events before the time 
point of assessment, and lack of an established 
minimum clinically important difference for 
therapeutic effect. Different primary outcomes, 
including the time until recovery or hospital 
discharge, have been selected for other studies.27
The lack of standardized treatment across 
trial sites and countries is an important limita-
tion of our trial, since there was extensive poten-
tial for interactions with antiviral drugs and 
glucocorticoids. More patients in the placebo 
group than in the tocilizumab group received 
concomitant glucocorticoids; however, this im-
balance is unlikely to have obscured a signifi-
cant treatment effect because mortality was 
similar in the two trial groups regardless of 
glucocorticoid use and was higher in patients 
who received glucocorticoids than in those who 
did not in each group (Table S10). In addition, it 
is possible that worsening clinical status among 
patients in the placebo group could have led to 
increased glucocorticoid use and more frequent 
administration of a second dose of placebo. Pa-
tients who received a second dose of either toci-
lizumab or placebo generally had worse out-
comes (Fig. S7), which may reflect a selection 
bias, because only patients whose condition did 
not improve after the first dose could be consid-
ered for a second dose. The administration of 
tocilizumab typically results in decreased CRP 
levels and in increased interleukin-6 levels; 
therefore, to minimize the risk of unblinding 
among investigators, both levels were measured 
in central laboratories and not reported to the 
trial sites.
Among all the trial patients, the range of the 
time from the onset of symptoms to baseline 
was 1 to 50 days. Of note, there was no clear 
pattern of responses in patients who were treat-
ed earlier rather than later in the course of ill-
ness (Fig. S7), whereas other studies have shown 
different responses.28
Since the time when our trial was initiated, 
Figure 2 (facing page). Changes in Clinical Status  
and Hospital Discharge.
Panel A shows the time until improvement from base-
line by at least two categories on the seven-category or-
dinal scale that was used to assess the patients’ clinical 
status. Panel B shows the number of days until hospital 
discharge or readiness for discharge by day 28. Data in 
Panels A and B are plotted as 1 minus the Kaplan–Meier 
estimator. Data for patients who discontinued the trial 
or were lost to follow-up for any reason were censored 
(indicated by hatch marks) at the time of their last ordi-
nal-scale assessment. Data for patients who died were 
censored at day 28. Panel C shows the patients’ clinical 
status as assessed on the seven-category ordinal scale 
at day 28, according to the category at baseline. Catego-
ries on the ordinal scale were as follows: 1, discharged 
or ready for discharge; 2, hospitalization in a non–inten-
sive care unit (ICU) without supplemental oxygen; 3, 
non–ICU hospitalization with supplemental oxygen; 4, 
ICU or non–ICU hospitalization with noninvasive venti-
lation or high-flow oxygen; 5, ICU hospitalization with 
mechanical ventilation; 6, ICU hospitalization with ex-
tracorporeal membrane oxygenation or mechanical 
ventilation and additional organ support; and 7, death. 
Data in category 6 include a patient who died on trial 
day 1 but had been assigned to category 6 on that day 
before receiving placebo.
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there has been substantial evolution in our un-
derstanding of what constitutes standard care 
and of the natural history of Covid-19 and its 
associated complications. On the basis of cur-
rent knowledge, effective treatments and mean-
ingful outcomes for clinical trials are likely to 
differ for different stages of disease. Future tri-
als should be more narrowly focused or enroll a 







Patients with ≥1 event — no. (%) 228 (77.3) 116 (81.1)
No. of events 778 360
Any serious adverse event — no. (%)
Patients with ≥1 event 103 (34.9) 55 (38.5)
No. of events 160 101
Death — no. (%) 58 (19.7) 28 (19.6)
Patients with adverse events of special interest — no. (%)
Infection 113 (38.3) 58 (40.6)
Serious 62 (21.0) 37 (25.9)
Opportunistic* 1 (0.3) 1 (0.7)
Medically confirmed cancer 1 (0.3) 0
Hypersensitivity† 19 (6.4) 4 (2.8)
Anaphylaxis per Sampson criteria 0 1 (0.7)
Hepatic event 5 (1.7) 3 (2.1)
Abnormal liver-function value‡ 6 (2.0) 6 (4.2)
Myocardial infarction 3 (1.0) 2 (1.4)
Stroke 3 (1.0) 2 (1.4)
Bleeding
Any 45 (15.3) 16 (11.2)
Serious 13 (4.4) 5 (3.5)
Serious infection reported in >1% of patients in either trial 
group§
Covid-19 resulting in death 39 (13.2) 18 (12.6)
Septic shock 7 (2.4) 6 (4.2)
Pneumonia
Any source 7 (2.4) 4 (2.8)
Bacterial 6 (2.0) 2 (1.4)
Sepsis 3 (1.0) 4 (2.8)
Bacteremia 2 (0.7) 3 (2.1)
*  Opportunistic infections were reported in one patient with candida sepsis in the tocilizumab group and in one patient 
with respiratory moniliasis in the placebo group.
†  Hypersensitivity reactions include all events that occurred during or within 24 hours after the infusion of tocilizumab 
or placebo and that were assessed by the investigator as being related to the infused agent, regardless of whether the 
episode was clinically consistent with hypersensitivity.
‡  The determination of an abnormal liver-function value was based on the criteria of Hy’s law. Included among these ab-
normalities was an alanine or aspartate aminotransferase level of more than three times the upper limit of the normal 
range (ULN) with a bilirubin level of more than two times the ULN.
§  Listed are the preferred terms in the Medical Dictionary for Regulatory Activities, version 23.0.
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larger number of patients to allow for further 
stratification on the basis of disease severity and 
other baseline characteristics.
Results of this trial must be interpreted in the 
context of therapies for severe Covid-19 pneumo-
nia. Among the treatments for hospitalized pa-
tients with Covid-19 that have been investigated 
in randomized, controlled trials, dexamethasone 
was found to reduce mortality only among pa-
tients who were receiving mechanical ventilation 
or supplemental oxygen at randomization.28 
Remdesivir shortened the time until recovery but 
did not have a significant effect on 14-day mor-
tality.27 Clinical trials are under way to investi-
gate many potential treatments, including other 
antiviral and antiinflammatory drugs, other 
targeted immunomodulators (e.g., sarilumab, 
anakinra, baricitinib, and canakinumab), anti-
coagulants, and antifibrotics (tyrosine kinase 
inhibitors).29 However, the need for effective 
treatments for patients with severe Covid-19 
pneumonia continues to be a major challenge at 
this point in the pandemic.
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